Literature DB >> 21384311

Percutaneous pulmonary valve implantation after endocarditis of Contegra® valved conduit: a case report.

G Palma1, R Giordano, V Russolillo, C Vosa.   

Abstract

This report describes the case of a 13-year-old boy with endocarditis of a Contegra® pulmonary valved conduit used for the correction of tetralogy of Fallot. He had severe pulmonary stenosis after endocarditis resolution. We performed percutaneous pulmonary valve implantation with resolution of the conduit dysfunction. The procedure was well tolerated by our patient and offered many advantages. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21384311     DOI: 10.1055/s-0030-1250214

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  4 in total

1.  Percutaneous implantation of the Edwards SAPIEN(™) pulmonic valve: initial results in the first 22 patients.

Authors:  Nikolaus A Haas; Axel Moysich; Ulrich Neudorf; Hojjat Mortezaeian; Mohamed Abdel-Wahab; Heike Schneider; Daniel De Wolf; Jerome Petit; Sreeram Narayanswami; Kai Thorsten Laser; Eugen Sandica
Journal:  Clin Res Cardiol       Date:  2012-08-30       Impact factor: 5.460

2.  Right-sided infective endocarditis: recent epidemiologic changes.

Authors:  Shi-Min Yuan
Journal:  Int J Clin Exp Med       Date:  2014-01-15

3.  MR and CT imaging of pulmonary valved conduits in children and adolescents: normal appearance and complications.

Authors:  Estelle V Tenisch; Leonor T Alamo; Nicole Sekarski; Michel Hurni; François Gudinchet
Journal:  Pediatr Radiol       Date:  2014-07-17

4.  Risk Factors and Patient Profile of Infective Endocarditis due to Gemella spp.

Authors:  Pramod Theetha Kariyanna; Bayu Sutarjono; Naga Pranavi Ellanti; Apoorva Jayarangaiah; Amog Jayarangaiah; Harshith Priyan Chandrakumar; Ashkan Tadayoni; Moro O Salifu; Isabel M McFarlane
Journal:  Am J Med Case Rep       Date:  2020-12-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.